Introduction: Implantation of penile prosthesis is constantly growing but little long-term data is available concerning the associated factors of prosthesis survival. Our aim was to describe the long-term survival of penile prostheses and to identify factors influencing long-term prosthesis survival.
Methods: This is a retrospective, monocentric cohort of patients who underwent their first implantation of a penile prosthesis, between May 2000 and March 2017, at the Reims University Hospital. Prosthesis survival was calculated by the Kaplan-Meier method. A univariate and multivariate analysis to estimate the risk of surgical removal/revision of the prosthesis was performed using a Cox model.
Results: 150 patients were included, and 61 patients underwent surgical removal of the prosthesis (40.7%). Mean follow-up was 76.12 months (0-176 months). Prosthesis survival was 69.7% at 5 years (95% CI, 62.2-77.3) and 58.5% at 10 years (95% CI, 50.0-66.9). In multivariate analysis, the factors influencing prosthesis survival were: type of prosthesis (other vs. Coloplast TITAN®, HR 1.89, CI 95%, 1.03-3.45) and prosthesis final length (20-29cm vs. 12-17cm, HR 0.27, 95% CI, 0.09-0.77).
Conclusion: At 10 years, the penile prosthesis survival is close to 60%. Type of implant and final length of the prosthesis may have a significant influence in long-term prosthesis survival. Patients undergoing penile prosthesis implantation must be informed about the risk of surgical removal/revision of the prosthesis.
Level Of Evidence: 3.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.purol.2020.09.018 | DOI Listing |
Evid Based Dent
January 2025
Eastman Dental Institute, London, UK.
Design: A retrospective cohort study assessing the mid-to-long-term outcomes and risk factors affecting the prosthetic success and survival of implant-supported cross-arch fixed dental prostheses (IFCDPs) with monolithic zirconia frameworks.
Cohort Selection: Forty-seven patients received a total of 51 cross-arch prostheses (27 maxillary and 24 mandibular prostheses), supported by 302 implants. Comprehensive clinical and radiographic records were available over a follow-up period ranging from 5 to 13 years.
JACC Cardiovasc Interv
January 2025
Institut Cardiovasculaire Paris-Sud, Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France. Electronic address:
Background: The prevalence of coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is high. Treatment of a coronary events (CE) after TAVR can be technically challenging.
Objectives: The authors sought to assess the incidence and prognostic impact of CE after TAVR.
Heart
January 2025
Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India
Urol Res Pract
January 2025
Department of Urology, Medistate Kavacık Hospital, İstanbul, Türkiye.
Objective: To analyze data from patient information forms (PIFs) submitted to the manufacturer of a new 3-piece inflatable penile prosthesis (IPP), the Rigicon Infla10® , to summarize interim outcomes of 250 implantations in a single center, which is the largest series in Türkiye.
Methods: A retrospective review of PIFs from 250 patients implanted with the IPP between January 2021 and December 2023 was performed to assess patient characteristics, surgical data, device durability, patient satisfaction, and rates of reoperation for any reason.
Results: The mean ± SD (range) follow-up was 21.
Eur Heart J Case Rep
January 2025
The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Background: Self-expanding valves used in transcatheter aortic valve implantation (TAVI) are designed to allow recapture and repositioning, facilitating optimal placement and mitigating conduction disturbances and paravalvular leakage. Here, we present a rare case in which the Navitor (Abbott Structural Heart, Santa Clara, CA, USA) could not be recaptured.
Case Summary: An 81-year-old Japanese woman with very severe aortic stenosis and a massively calcified nodule at the non-coronary cusp (NCC) underwent TAVI with a 25 mm Navitor valve.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!